AzTrials
AzTrials

Subarachnoid Hemorrhage, AneurysmalPhase 1RIPC-SAHNCT01158508

Remote Ischemic Preconditioning in Subarachnoid Hemorrhage

A Phase 1 study testing Remote ischemic preconditioning in people with Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Hemorrhage, run by University of California, Los Angeles at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Rupture of brain aneurysms is a common cause of death and disability, accounting for as many as 10% of stroke cases in the United States. While much of the resulting injury to the nervous system is caused by the initial bleeding from the aneurysm, many of these patients develop cerebral vasospasm, pathological… Read more about this study

Who is it for?
Any age
What is being tested?
Remote ischemic preconditioning
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
Apr 2010to Jul 2014
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Diagnosis of recent aneurysmal subarachnoid hemorrhage.
  • Definitive treatment of the aneurysm by surgical clipping or endovascular coiling has been completed.

Who cannot join

  • Patients with unprotected (untreated) cerebral aneurysms.
  • Patients with a known history of lower limb vascular disease, lower limb vascular bypass surgery and/or peripheral neuropathy.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UCLA Ronald Reagan Medical Center

    Los Angeles, California, 90095

Other trials in United States

About this study

Official title: Prophylactic Remote Ischemic Preconditioning for Cerebral Vasospasm Following Subarachnoid Hemorrhage

Rupture of brain aneurysms is a common cause of death and disability, accounting for as many as 10% of stroke cases in the United States. While much of the resulting injury to the nervous system is caused by the initial bleeding from the aneurysm, many of these patients develop cerebral vasospasm, pathological constriction of the blood vessels supplying the brain, several days following hemorrhage. As many as a third of patients can suffer a resulting neurological deficit and stroke, presumably caused by the decreased blood flow to the brain (ischemia). This delayed brain injury accounts for a significant percentage of poor outcomes following aneurysm rupture. Studies have shown that remote ischemia to many organs can precondition other tissues (including the brain) to be more tolerant to decreases in blood flow. This "remote ischemic preconditioning" has the promise of protecting the brain from ischemic injury. Whereas in other forms of stroke the onset of ischemia cannot be predicted in the general population, following aneurysm rupture the investigators know which patients are likely to develop vasospasm and when. Therefore, ischemic preconditioning following aneurysm rupture may help prevent some of the ischemic injury caused by vasospasm. Remote ischemic preconditioning by transient limb ischemia (produced by inflation of a blood pressure cuff on the arm or leg) has been shown to minimize injury to other organs, most notably the heart. Remote ischemic preconditioning of the brain following aneurysm rupture has not yet been investigated.

Read the detailed description

Phase I prospective clinical study to evaluate: the tolerance of clinical subjects with Subarachnoid Hemorrhage (SAH) to the maneuvers involved in the generation of Remote Ischemic Preconditioning (RIPC), the immediate and delayed hemodynamic effects of the RIPC in the cerebral vasculature, in terms of Transcranial Doppler (TCD) velocities, pulsatility index variations, Cerebral Blood Flow (CBF) measures, and cerebral arterial flow measurements using Magnetic Resonance Imaging with flow measurement capabilities (MRI NOVA). As a secondary goal, we will be valuating the impact of RIPC in the incidence of vasospasm, delayed neurological deficits, development of ischemic lesions in MRI and clinical outcome.

Patient Enrollment: Patients who are admitted to the University of California Los Angeles (UCLA) Ronald Reagan Medical Center with a diagnosis of aneurysmal subarachnoid hemorrhage will be considered for inclusion in this study. As is standard of care for this condition, following admission patients' aneurysms are generally treated by one of two methods, surgical clipping or endovascular coiling. Following this definitive treatment of the aneurysm, generally performed emergently in the first 24 to 48 hours following hemorrhage, patients will be consented and enrolled in the study. No patients with unprotected (untreated) aneurysms will be enrolled. Patients with a known history of lower limb vascular disease or lower limb vascular bypass surgery will be excluded.

Remote Ischemic Preconditioning (RIPC) Procedure: Following enrollment, patients will receive four rounds of lower limb remote ischemic preconditioning, starting at the earliest post-hemorrhage day possible following definitive treatment of their aneurysm. The remote ischemic preconditioning will typically take place on post-hemorrhage day 2, 3, 6 and 9. Each cycle of RIPC will consist of four 5-minute cycles of lower limb ischemia following by 5-minute periods of reperfusion. A large blood pressure cuff will be wrapped around the upper thigh of one leg. The cuff will be inflated to a pressure 20 mm Hg greater than the systolic arterial blood pressure measured by the patient's arterial line or upper limb blood pressure cuff. The adequate level of inflation will be confirmed by the absence of pulse in the ipsilateral pedal artery as detected by Doppler. The cuff will remain inflated for 5 minutes. The cuff will then be deflated and the limb will be allowed to re-perfuse for at least 5 minutes. After the cuff is deflated, the same procedure will then be repeated three times for a total of four cycles.

Evaluation of Tolerance to the RIPC Maneuvers: The patient will be continuously monitored for pain and discomfort during the RIPC session. If the patient pain is more than 6 in the traditional 1-10 scale or if the patient expresses their desire to stop the maneuver, the procedure will be stopped, and the data regarding number and duration of the maneuvers will be recorded. A down-escalation of the treatment will be proposed, by reducing the number of cuff inflations to 3 or 2, as tolerated.

Hemodynamic evaluation of the effect of RIPC Maneuvers: Transcranial Doppler (TCD) measurements will be performed during the RIPC session. TCD and Cerebral Blood Flow (CBF) measurements will be performed at 24 hours and 72 hours after treatment.

Cerebral arterial flow magnetic resonance imaging (MRI NOVA) will be measured the first day after treatment and 72 hours after treatment in patients suitable for transport to the MRI scan per Intensive Care Unit (ICU) clinical team criteria.

Clinical assessments of the patients will be performed daily and at discharge from the ICU

Treatment of subarachnoid hemorrhage (SAH) and Vasospasm: Aside from the RIPC procedures, all other treatment and monitoring of the patients will be as is standard of care for the treatment of patients with subarachnoid hemorrhage in our hospital. Patients will undergo neurological monitoring in the intensive care unit. Monitoring for cerebral vasospasm, including transcranial Doppler studies, angiograms, cerebral blood flow studies, Computed Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans and regular neurological examination will be performed as standard. Likewise, prophylaxis and treatment for vasospasm or any other complications of subarachnoid hemorrhage will be performed as usual, as is the standard of care. Apart from the rounds of RIPC, in no way will the monitoring and treatment of these patients differ from patients not enrolled in this study.

Data Collection: Patients' clinical data will be collected in a password-protected study computer database. General patient demographics, past medical history, history of present illness, Hunt \& Hess grade, admission Glasgow coma score, modified Rankin score, size and location of aneurysm, dates of subarachnoid hemorrhage and aneurysm treatment, type of aneurysm treatment, transcranial Doppler study values, cerebral blood flow measurements, and results of clinical examinations will all be noted and recorded in the study database. Additionally, clinical imaging studies performed (including CT scans, MRI scans and cerebral angiograms) will be reviewed and their findings noted. Specifically, size and location of aneurysm, extent and location of subarachnoid hemorrhage, Fisher grade, and presence and size of ischemic brain lesions will be noted. Clinical complications and outcomes will be recorded, including occurrence of angiographic vasospasm and delayed neurological deficit and condition at discharge and follow-up (Glasgow outcome score and modified Rankin score). Any complications associated with the RIPC procedure will be noted and reported appropriately.

Being tested
Remote ischemic preconditioning
Keywords
cerebral aneurysm, cerebral vasospasm, subarachnoid hemorrhage, remote ischemic preconditioning
Medical subject headings
Subarachnoid Hemorrhage, Vasospasm, Intracranial, Intracranial Aneurysm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Remote ischemic preconditioningProcedure or surgery

    Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.

Study groups in NCT01158508
Study groupRoleWhat they receive
Remote Ischemic PreconditioningExperimentalPatients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
Receives: Procedure: Remote ischemic preconditioning

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occurrence of neurological events, or vasospasm

    Measured: At days 3

  2. Occurrence of neurological events, or vasospasm

    Measured: At day 7

  3. Occurrence of neurological events, or vasospasm

    Measured: At day 15

  4. Occurrence of neurological events, or vasospasm

    Measured: At day 30

Secondary outcomes (3)
  1. Transcranial Doppler Measurements and metabolic assessment

    Measured: At days 3

  2. Transcranial Doppler Measurements and metabolic assessment

    Measured: At day 7

  3. Transcranial Doppler Measurements and metabolic assessment

    Measured: At day 15

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2010 (estimated)
  2. Study startApr 2010
  3. Primary completionJan 2014
  4. Study completionJul 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01158508
Sponsor's protocol ID
09-08-081-01
Acronym
RIPC-SAH
Status last verified
Nov 2016
First submitted
25 Jun 2010
Last updated
28 Nov 2016
Results posted
No
Data monitoring committee
No

Publications

  • Gonzalez NR, Connolly M, Dusick JR, Bhakta H, Vespa P. Phase I clinical trial for the feasibility and safety of remote ischemic conditioning for aneurysmal subarachnoid hemorrhage. Neurosurgery. 2014 Nov;75(5):590-8; discussion 598. doi: 10.1227/NEU.0000000000000514.

    PubMed 25072112

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Remote ischemic preconditioning in people with Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Hemorrhage, run by University of California, Los Angeles at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occurrence of neurological events, or vasospasm (time frame: At days 3). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01158508, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2016; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in